<SEC-DOCUMENT>0001193125-15-219927.txt : 20150611
<SEC-HEADER>0001193125-15-219927.hdr.sgml : 20150611
<ACCEPTANCE-DATETIME>20150611073052
ACCESSION NUMBER:		0001193125-15-219927
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150611
FILED AS OF DATE:		20150611
DATE AS OF CHANGE:		20150611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		15924832

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d941559d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 11, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 7, 151 Macquarie Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 11, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prima BioMed receives a Research Tax Credit cash rebate in France.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d941559dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g941559g59j01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11&nbsp;June 2015 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED RECEIVES A
RESEARCH TAX CREDIT CASH REBATE IN FRANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the
&#147;Company&#148;), a leading <FONT STYLE="white-space:nowrap">immuno-oncology</FONT> company, is pleased to announce that it has received &#128;226,055 (approximately A$320,000) in a cash rebate from the French state under the Cr&eacute;dit
d&#146;Imp&ocirc;t Recherche scheme. The cash rebate was paid in respect of expenditure incurred by Prima&#146;s wholly owned subsidiary, Immutep on French R&amp;D activities in the 2014 calendar year, related to the Company&#146;s LAG-3 programs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Cr&eacute;dit d&#146;Imp&ocirc;t Recherche&#148; (CIR), meaning &#147;Research Tax Credit&#148;, is a French government tax incentive first
introduced in 1983 by which French companies doing research and development activity in Europe can be reimbursed 30% of eligible expenditure. Unlike most direct aid to R&amp;D and innovation in industrial countries, the CIR system does not target
any specific sector or type of company. Expenditure eligible for CIR includes salaries for researchers, operational expenses, depreciation of assets used in research projects, intellectual protection expenses and technology watch expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima is eligible to receive CIR credits because it has a laboratory at Ch&acirc;tenay-Malabry in southwestern Paris. The laboratory is a leading centre of
immunology research in Europe. The Ch&acirc;tenay-Malabry facility is headed by Chief Scientific and Medical Officer Professor Fr&eacute;d&eacute;ric Triebel. Prima inherited the laboratory with its December 2014 acquisition of the French company
Immutep SA. It is currently working on new products in addition to development of the existing Prima pipeline, which includes the lead compound IMP321 entering Phase IIb trial in metastatic breast cancer patients receiving first-line chemotherapy.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s CEO, Marc Voigt, commented &#147;Immutep is one of the fruits of the French state&#146;s long-standing support of cutting edge R&amp;D in a
commercial setting, via CIR and other schemes. Professor Triebel&#146;s lab has already created multiple immunotherapy products of great prospective value over the last two decades, and we at Prima look forward to the later stage clinical work which
we believe will show the value of this support.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer. Prima
BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au&nbsp;&nbsp;&nbsp;&nbsp; ABN: 90 009 237 889 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s original product, called CVac, is an <I>ex vivo</I> dendritic cell priming therapy that in May 2015
yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune
response. IMP321, which is a soluble form of LAG-3, is an antigen presenting cell activator (&#147;APC activator&#148;) that induces T cell immunostimulation for cancer chemoimmunotherapy. IMP321 has completed early Phase II trials. A number of
additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed
Ltd: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart Roberts, Global Head of Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;447 247 909; <U>stuart.roberts@primabiomed.com.au</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USA Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Holdsworth, ProActive Capital
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;862 4607; adamh@proactivecapital.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755; mgregorowski@citadelpr.com.au </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Axel M&uuml;hlhaus,
edicto GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69 905505-52; amuehlhaus@edicto.de </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au&nbsp;&nbsp;&nbsp;&nbsp; ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g941559g59j01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g941559g59j01.jpg
M_]C_X``02D9)1@`!`0$`;0!M``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``@%!@<&!0@'
M!@<)"`@)#!,,#`L+#!@1$@X3'!@='1L8&QH?(RPE'R$J(1H;)C0G*BXO,3(Q
M'B4V.C8P.BPP,3#_VP!#`0@)"0P*#!<,#!<P(!L@,#`P,#`P,#`P,#`P,#`P
M,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,##_P``1"`!]`J@#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#W^BBBI`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`***0F@!:*@CNH))WA216ECP64'E?K4V:`%HJ.2
M18T9W.%49)]!3;:XBN8UE@D62-QE64Y!%%F!-1113L`4444@"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****+`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`AKSKXF>.+G3-6L?"^AA3J>IE4,QY^SJQQNQW->BMTKYLU;4O
ML'[0QN=1/[M+U$RW15*@*?UH0'N-K:6_@[PS(P>2Y>!#)+-(<R3-ZL:\XU#X
MC:Y=2EK=X[6/LJ+D_F:]>U&TBU'3YK6?F.="IQZ&O*-3^&NKP7+_`&+R[B$G
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MHL]-U,&Y;A8IHVC+>PW#G\*C\1_%'POX<U:73-5NYX[J(`LJ0,PY&1R!7C'C
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M">G"^UJX,,+.$7:I9F)]`*Y;X"7_`-J^'MO#(^Z2RFDMV&>1@Y'\ZY/XF!?'
M/Q7TKPJKM]DM%WW!4]\9;]`!^-%@/6/"WB33?%.F+J.CS-+;EBF64J01U&#6
MO7B/P>NF\(>/M7\&7I*I-(9+;/0X&1^:_P`J]N!S18#F_&'CG0_![VZZY/+$
M;D$Q[(B^<=>GUK'TSXP>#-2OH[2#5&CED.U?.@9%S[DC`KAOVG&5+_P\[KN4
M%R1C/&5KG/'NJ:-XSN](T[P[HZ:9=A@)+FX1;=6&!Q[^M`'NWBGQIHWA86AU
MB=XQ>-MB*1E\GCT^M:M]JEGI^GM?WMPD%LB;VD<X`%>*_'F!K32O"%L\GFF)
M@A<'.["J,U9^+S/KOBOPIX5:1DM9]DDH4]<G'\@:+`=G9_&#P5=WJ6J:LR.Y
MPK20.BG\2*[A'5T#HP96&00<@BN)\3_#CPW=>$[BQ@TNVMW@A9H)8XP'1@"0
M<]37-?"'Q6UK\*-0GU&0L-(,B*Q/48RH_,XHL!WVA^,M&UW5K[3--N6ENK`X
MF4H0!SC@GKS4]CXGTN_\07FAVTY>^LE#S)M.`#[]^M?._P`']7GT#QLM]?DQ
M6^IVLTI=NC`$G/YK5_X2ZAJ"?$RUUB\)\C7GG0,3][!S_/%%@/8O$_Q-\,^&
M-4.FZM<S1W*H'(2!G&#G'(^E1^'/BEX7\2:O#I>E7<TEU-N*JT#*#@9/)]A7
MF'Q'U*RTGXZVM]J=N;FTA@C+QK&)"PPP^Z>O6O1?`_B_POXCU@VVC:.]I<Q1
MF3S'LUBP.AP1]:8$VN_%CPIH.K3Z9J5W.ES;MMD5;=F`/U%7/#?Q)\*^([D6
MVF:HAN&Z12HT;-]-P&:\RTBV@O/VC-2ANH(YXCYF4D0,/N#L:O?'7P%I5EH3
M^(M&MX["ZMI%,@A&U7!(&<#H1[4`>U`YI:YGX8ZK/K7@72;^[.9Y(<.?[Q!(
MS^E=-4@%%%%`!1110`45#%<P3#,,T<@_V6!J7(]:5QVL+129HS3$+129HH`6
MBBBJ`***2I8"T444`%%%%-`%%%%,`HHHJ0"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
M->+?M!>!);Z(>)=+C+30*%N44<LHZ,/I7M--=%D4JZAE(P01G--`>&?"+XO)
MY<6B>*9@FP!(+M@>>VU_\:]QBD25`\;JZ,,@J<@BO$OBI\&?/:75O"40$ART
MMGT#>Z>_M7(Z;X^USP)H)T=+XW-^X_U4OS+8K_=_WO;H*8'NWCSQQI7@W3S-
M?2A[AQB*W7EG/T[#WKY\MDU[XN^-T:883.'*YV6\0.2![U%X3\*>(?B;K,EW
M<SR/"&_?WDQX7_9'J<=A7TGX,\):7X1TM;'2HL#K)*P^>1O4F@#0T/3+?1M+
MM].LEV06T8C0>PKQSXQ6']H?%GPW%+:F>W8(D@*$J07Z&O<::T:,P9D4L.A(
MY%`&;I/AS1M&R=+TRUM">IBC`/YUXWK%DT_[1D)EM3+;EHP2T>4QY?N,5[Q3
M/*CW[]B[O[V.:`/"/&>FR^`?BUI^NZ9;%=.O7&^.%#A>@<$#\ZG^(L4LWQP\
M.SQQ.T7[@E@IP/F/4U[@\22??16^HS088R0Q12PZ$CD4`>2>&+8^)?C5KNJR
MI(;:PM_LL)92`3PIQG\:P?A)X+GLOBCJGVU'\C22_E%@=I+'`(_`FO>4B1,[
M$5<]<#&:41JI)50">I`ZT`>+_#VZ?P5K_C2QNDD6SMB;J+Y"=W/&/7J*Q/AI
MX%U;Q:VH>);G6+W2;B>X95>)<,X/)Z].N*^@3#&228T.[KE1S3E14&$55'H!
M0!\Z_$/PGJ_@+7=)\1VFI7FKS>;\TTJ[F4CL<=B":^@-'O5U'3+:\3[L\2R`
M8P1D9JT\:.,.H8=<$9I54*,*`!Z"@#Q#]I:.5K_P^\4,D@CWLVQ2<<K61\2?
M%L'CC2+'2-"\/WDEVDB_OG@(*<8P/K7T(\4<F/,16QZC-"PQH<K&JGV`%`'@
MOQ=TR_M?#/@NTNEDFN;?"2D`M@X'I^5;GQCTC4+6Y\/^+M)MFN)=+V><B\D*
M,$''7UKU]XT?&]%;'3(SBAD5E(8`@\8(H`\AUSXUZ/>^'Y[;18;N75;B,QI"
M83\K$8_&N:U?1[_PO\&K;1YH)/[1UJ\#2JHW%%Z@''T%>ZP:'I5O<FX@TVTB
MF//F)"H;\\5=:*-\;T5L>HS0!X7\:_"'V/PSX972K=S);8M#Y8)(##OCWJY\
M2M"?PEX6\)3:5"YDTFY4,44DY(RV<>I!KVED5AAE!^HH:-'&'56'H1F@#P'Q
MQJ::7\:[#7+FUGGM(K>-V\N,MG*M_B*]#\+_`!,T;Q!K<&FV6GWL$TP;#RP;
M%&!GDUW+0Q,<M&A/3E10L$2ME8D4CN%%`'SY=ZRGA?XZZIK%]:74MLK.O[F(
ML22H`JQXX\1^(?BA-#H7AW1KNWTYG#22S+MW_P"\>@`KWMH(6.6B0D]RHIR(
MB#"*%'L,4`9/@_14\/>&[#24.?LL04GKD]3^M;%%%)@%%%%(`HHHH`^<(II8
MCF.1T/\`LL15Z'7-6A'[K4KM?;S6Q_.JSZ?>Q?ZVTG3_`'HS4+*RG#`@^XKP
MO>1^D.-*>K2?W&W#XPU^'E=3F/LV&_G6C;?$378_]8\,W^\G^%<D>*7\ZI59
MKJ92P6&EJX([8?$W5P/^/:T/_`6_QJU:_$^ZQ_I5G$W_`%SR/YFN`%+5*O5[
MF$LMPLE\!ZE;_$ZP;'G6<Z'VP:NQ_$70F^^TZ?6,G^5>0C%'>M%BJB.66389
M[71[5;^-M!G;`OU3_?4K_,5HPZ]I4P_=W\#?\#%>#`XIP]:T6,EU1A+(Z?V9
M,^@4O+5_N7$;?1Q4H=6^ZP/T-?/>]AT=A]#5F#4;R'_4WD\?^[(15K&=T<TL
MBE]F?X'ON:,UXC#XEUF(8349\>[9JW'XRUU/^7TM_O*#5K&1ZHP>2UELT>Q]
MZ6O)X/'^L1_>\F3W9,5;C^(NH_QVL!^A(JEBZ1C+*<2NB^\],I:\]@^(TG'G
MZ>OU63_ZU7X?B'8L/WMM*A]B#5+$4WU,99=B8_8.SHS7+)X\TAOO><O_``"K
M$7C/19/^7DK_`+RD5:JP?4Q>$KQW@SH:*RHO$.E2_<OH?Q;%65U.R?[MW`?I
M(*I23V9BZ<UNG]Q<HJ%;J!_NRQM]&%2*P/0BJ1-F.HII-+FFR;BT4E%(8M%)
MFB@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****=@"BBBD`4444`%%%%.P!
M1110!R_Q-UR;P[X)U+4+;_7)'MC(_A+<9KQ'X;_"J7QEH]WK&KW$\'F[OLSA
MQF5^[-D'C-?0OB'2+;7=&NM-OAF"Y0HV.H]Q6?X*TN;0/#L&D3C=]B!C21>D
MBY.#['VI@>0?`>34_#OCW4?"M[\J%7:2/.0'7^(?45]`5Q^@>$O)\9ZGXHO`
M%N;H"*",#_5Q@#D_[1Q784`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%(`HHHI`%%)FB@!IB0CE0?J*IW.CZ=
M=?\`'Q8V\F?[T8-7Z,4FD]RE*2V9@2^#/#\O73(5_P!P%?Y5G7'PYT.4YC6:
M'_=D/]:[#%%3[*#W1O'%UX;3?WG`3_"^R(/DWTZ'MN4-69<_#"]7/V:^AD';
M>A4_UKU*BH>'IOH=,<TQ4?M7/'IOAWKD?W%ADQ_=?'\ZS;KPGKEL?GTV9AZH
M-W\J]R^E)MSUYJ'A(/8Z8YUB%O9GS_+IM]#_`*ZSN$_WHF%0E"O#*5/H:^A2
M@/!`_*J\^G6<XQ-;0R#_`&D!K)X-=S>.>/[4#P+%.7@<U[9+X5T.7[VF6XS_
M`'4V_P`JI7'@+0Y?NP/%_N.?ZUF\'/HSICG=)_%%H\B7%.%>GR?#?2V_U=Q<
M)^(-9]Q\-",_9=0&/1X_\*S>%J(Z(YOAI=6OD<"13@:ZZ7X=ZHOW)[=_ID53
MG\$ZW!]VW64?[#BH]C470V6.PTMIF`.E%:,F@ZM#Q)I]P,=PA-5WL+N,_O+:
M9?JAJ7"2W1LJU-[21$/>E'-(58<%2/PI1Q4-%73V'8Z4X$BD[4HH$[$HD=?N
MNP_$U8AU&\B_U=U,OT<U5I5JE*2V9C*G![HU(]>U5>E]/^+9J>/Q-JZG_C]<
M_4"L=>M.%5[2:ZF3H4GO%?<=`GB[55ZS(WU058C\9ZD/O)$WX5S0ZT\52K3[
MF+P="7V4=2GC:]'WK:$CZD5:B\<'_EI9#_@,G_UJX\4]*T5>:ZF4L!A_Y3M4
M\:VY^_:2CZ$&IT\7V+#)CE'X"N%Z4HYJEB9HQ>743OD\5Z<W4R#ZK4R>(],?
M_EXV_52*\_7BGKP>*OZS(R>64N[/14UG3FZ7<7XMBI!J5F>ES"?^!BO.<\BG
M#UJEB7V,WEL>DCTA;RV;[L\9_P"!"GB:,])%/T->;*:>KLO1B/QJOK-^AF\M
M[2/2`ZGH12YKSE;B9?NS./HQIZZA=K]VYE'_``,T_K"[$O+9=)'H=+FO._[4
MOUX%W+_WU2C6M27_`)>Y/TIK$Q[$O+:G='H5&:\]'B#4U/\`Q]$_51_A3QXF
MU0?\ME/U04_K4!?V;6Z6._HS7`GQ9J8_BC/_``&@>+]2'583]5H^LTQ?V;7.
M^S17!GQG?KUBA/X'_&G#QM>][:$_0FG]8IB_LZOV.ZR*,UPR^.+@?>LXS]'/
M^%2#QXW\5B/PD_\`K4_K-/N2\OQ"^R=MFDS7&#Q['_%8N/HXIX\?6O\`%9S#
MZ$4_;T^XOJ.(_E.PHXKD3X^LAUM9_P`Q0/'UAWMIQ^5'MZ?<GZEB/Y&=?17(
M_P#"?Z>/^7>?]*/^$_TW./(G_(4>WI]P^I8C^1G745R7_"?Z9_SQG_[Y%)_P
ML'2_^>-Q_P!\C_&G[>GW#ZEB/Y&==17(_P#"P=)SS'/_`-\T?\+!TC_GG<?]
M\C_&CVU/N+ZEB/Y&==17(_\`"P](_P">=Q_WR*0_$32/^>=Q_P!\C_&CVT.X
M_J.(_D9U]%<>?B)I/_/*X_[Y'^-)_P`+&TG_`)XW'_?(_P`:/;4^X?4L1_(S
ML:*XP_$C2A_RPN/^^1_C3?\`A96E_P#/O<_D/\:/;T^X_J&)_D9VM%<.?B9I
MO:TN?T_QIK?$W3^UE<G\1_C2^L4^Y7]GXG^1G=45P#_%"R'W;"X/_`EJ&3XH
MQC[FF.?K*!_2E]8I]REEN*?V#T3-&:\S?XHS?\L]+0?67/\`2J\GQ/U`_<L8
M!GU8FE]:I]S193BG]G\3U3-&:\D;XF:Q_#!:C_@)_P`:A?XDZXWW1;I]$_\`
MKU/UJF7_`&-BNR^\]AS17C,OQ#\0,.)XE^D8JI)XX\12'_D).O\`NHH_I2>+
M@C19)B7NU]Y[CFC</45X,_BO7I/O:I<8]F`_D*KRZYJTO^LU*[/_`&V:I^NQ
M[&L<BJO>2/?GGB3[\B+]3BJ\FK:?']^]MUQZR"OGV:ZGE/[V>5SZLY.:@/6I
M>-[(Z(Y`_M3_``/?IO%&B0@^9JEJ/I*#_*LRY^(/AZ'(%VTI':.,FO%!Q25#
MQDGLC>&0TOM29Z[-\3]'3/E0W,G_``$"LZZ^*Z`?Z+IC$^LDN/Y"O-,4C=*S
M>*J,Z89+A8[IOYG<3_%'5V)\JVMD'XFBN%HK/VU3N=*RS"K3D1],4445[)^?
M!1110`4444`%%%%`!1110`4444`%(:6B@!"*,4M%`";1Z4AC0CE0?J*=138%
M.;3;*;B6TA?ZH*JOX:T>3[^GP_@,5JTO:HY4]T:*K..S9ST_@S19/NVYC/\`
MLN:J2>`]-8?)),G_``+-=7S1BI=*#Z&L<77CM)G%3>`$/^IO6'^\M4G\!7JD
M[;J%_J"*]"HQ4/#TWT-EF.(7VCS:3P9JD?W1$_T:JDGAW5HCS92'W7FO5,>E
M&VH^JP9M'-:RWL>2-I5_']ZSG'_`#4+031G]Y$Z_52*]@VCT%-:&-@0R*?J*
MEX-=&:K-I=8GD'U.#[T]>E>JOIME)]^UA;_@`JO)H&F/ULHOP&*AX271FJS6
M/6)YH.E.!Q7H,OA32G/$++]&-0/X0T\CY&E7_@6:EX69:S.B^YQ`/-/!S75O
MX+C/^KNV'U7-0-X-N%^[=1L/=2*GZO-=#58^@_M'.@^M29XK9D\)WRC*O"WX
MFJS^']33@6^[W4TG2GV*6*HR^T9X;BE#9JTVDZB@^:SE_!<U$]G=QCY[69?J
MAI<LET-%5IO9HBS1FD;<O#*1]:;D4G<M-,7/--9O:DSZ4UJAC]`)ZTPGBE)I
MI;BD7883FD/%.J-J10A.:9FG<TP\4%(&.*8P[TXG(IA-24AI/%-ZTXFF-2*W
M$:FL<4M-:@JUA.M,S3CU%--`Q#3:4]Z:>E!:&YIK'FG4UNM!0E-)IQIIH*&E
MN*0TIZTAH&AC]:;3F/--H*04TFE[TC=*!B`TAI5Z4AZT%"4444#&FDI324`(
M>E)3CTIM`PH%%`H`0]:2E/6DH*"BBBD`&FYS3CTIM,`HHHH`^EZ***]X_+PH
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MBF@"BBBBX"4HHHI(`HHHIW`****+@(:,"EHQ20"8I-H]!3J*8$301M]^-6^J
MBH7TZSD^]:Q'ZH*MT4K(:DULS.?0].<<VD?X#%5W\,:8QSY!'T<_XULT5+C%
M[HT5:HMI,P)/"6GOT\U?HU59?!=L1^[NI%/^T`:ZFC%0Z4'T-(XJM':3..D\
M$R'[MZOXI_\`7J"3P5>#[MU"?J"*[BBI^KTWT-EF&(7VCSV;P?J:\J8G^C53
MF\,ZNG_+J6^A%>G4F!2^JP-%F=9;V/*GT+5%'-E+^`JM+I=_'G?9SC_@!KU[
M`HQ4/!Q[FJS:HMXH\7>"9#AXG7ZJ143<"O:FAC?[R*WU%0MI]FWWK6(_5!4/
M!^9NLX[P_$\9Y]*83UKV.31M-?[UC`?^`"JTGA?1I?O6,8^F16?U.71FBSBG
MUBSR0\]*0BO57\&Z*W2U*_1S4$G@;1V'"2K])#2^J3-5F]'JF>7-P"::3Q7I
M,OP^L&^Y<3I^1JK+\.8S]R_8?5/_`*]2\+4-HYKAGN[?(\^IIYKNY/AQ*/N:
M@I^J5!)\.K\#]W>0GZ@BI>'J=C=9EAOYSB#P:#75S_#_`%E?N&"3Z/BJDG@K
M74/_`!ZAOHPJ'1J+H:K'8>6TT<Z>M(36W)X2UQ.MA(?I@U`_AK6D&6TV<_\`
M`:EPDMT;+$T7]M?>8[=:2KTND:C&3YEC<+]8S59[:9/OPR(?]I2*7*UNC55(
M/:2^\A-(>E.92.Q_*FD''2E9EII]1`>*0T`<4F:#1!29I:2@8AI*.]%($!Z4
MVES24QA110:!H::*7%(>M`PHI*6D`'I3:<>E-I@%%%%`'TO1117OV/R\****
M+`%%%%%@"BBBBP!11118`HHHHL`44446`****+`%%%%%@"BBBBP!11118`HH
MHHL`44446`****+`%%%%%@"BBBBP!11118`HHHHL`44446`****+`%%%%%@"
MBBBBP!1113`****`"BBB@`HHHH`,4444K`%%%%,`I,4M%`"8HP:6B@!,44M%
M*P"8HQ2T4P&E0>PIIAC/6-#^%244K#NRLUC:M]ZWB/U45$VD:>_W[*`_6,5>
MHHLAJ<EU,N3PYH\GWM.MS_P`"JTG@[09#EM-A_#(K=HI<D>Q:K55M)_><X_@
M;P^W_+@H^C$5`_P^\/O_`,NK+])6KJJ*GV4.QHL776TW]YQTGPVT-ONB=/I(
M:K2?"_3"/W=W<I]2#_2NZHI.C3?0T6/Q*VFSSJ3X5P'/EZE*/J@-0M\*B/NZ
MG^<5>ET8J?J]/L:K-,4OMGE[_"NY_@U*/\8S_C5:3X6ZF.4O;9OJ"*]9Q28J
M7AJ78M9OBE]K\#QU_AGKJ9VM:2?]M#_A563X>>(U/%M$W^[**]KXI:GZK3-%
MG>*7;[CPU_`OB(?\P\_@X_QJ%O!GB).NF2GZ$?XU[P1Q2`4OJD#59YB.R/`W
M\+:ZF=VEW/X)FJLFAZK%_K--NQ_VQ;_"OH;:*,#TJ7@X]&:+/ZJWBCYP>SNH
<_P#66LR?[T9%%?1Q1?[HHH^IKN6N()?R?B?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
